BAM
RKDA icon

Blueshift Asset Management’s Arcadia Biosciences RKDA Stock Holding History

Blueshift Asset Management’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-735
Closed -$138K – 999
2019
Q3 		$138K Buy
+735
New +$141K 0.02% 665

Other funds holding RKDA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Blueshift Asset Management's RKDA Position: Q4 2019 in Review

Blueshift Asset Management sold out of Arcadia Biosciences (RKDA) in Q4 2019, closing a stake of 735 shares — an estimated $138K sold.

Blueshift Asset Management first reported a position in RKDA in Q3 2019 and held it in 1 quarter. The position peaked at $138K in Q3 2019. 14 funds tracked by Wall St. Rank hold RKDA as of Q4 2019.

  • Blueshift Asset Management reported no remaining Arcadia Biosciences position as of Q4 2019 after selling out during the quarter.
  • Blueshift Asset Management sold 735 Arcadia Biosciences shares in Q4 2019, an estimated $138K.
  • Blueshift Asset Management first reported a position in Arcadia Biosciences in Q3 2019 and held it in 1 quarter.
  • Blueshift Asset Management's Arcadia Biosciences position peaked at $138K in Q3 2019.
  • 14 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q4 2019.

Based on Blueshift Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.